$AARD Falls 12.9% After Securities Class Action Notice
Aardvark ($AARD) fell 12.9% on Aug 20, 2026 after a law firm publicized a securities class action notice tied to alleged misleading statements.
What Aardvark announced
Aardvark didn’t roll out a new product or earnings update — the day’s headline was a securities class action notice circulated by Schall, Brown & Schwartz LLP.
The notice says a complaint alleges the company made false and misleading statements to the market about the safety profile of its ARD-101 drug candidate and overstated ARD-101’s clinical and commercial prospects.
The notice also references purchases “pursuant and/or traceable” to the company’s Feb. 13, 2025 IPO and/or the period from Feb. 13, 2025 to May 14, 2026, and encourages shareholders who bought during the cited class period to contact the firm about potential lead plaintiff appointments.
What it means for Aardvark
Even when it’s “just a notice,” this kind of legal headline can put a spotlight on the gap between what a company previously said and what investors now claim was actually true.
If the allegations gain traction, it could raise questions about Aardvark’s prior messaging around ARD-101 — particularly on safety and how commercially viable the program is.
It can also become a time-and-attention drain for management, since litigation tends to pull focus toward legal process and away from day-to-day execution.
How the stock reacted
The stock started slightly higher, then slid hard as the session went on.
| Window | Move |
|---|---|
| 5 min | +0.6% |
| 10 min | -0.4% |
| 30 min | -0.4% |
| 1 hour | -6.5% |
| end of day | -12.9% |
On a market-adjusted basis, AARD underperformed SPY by 12.6% the same day.